secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210351
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q1 net loss widens to $1.69/shr; atacicept gets priority review with PDUFA July 7
--------------------------------------------------------------------------------

- Net loss of $121.0M in Q1 2026 vs $51.7M in Q1 2025; diluted EPS loss of $1.69 vs $0.81.
- Cash, equivalents and marketable securities at $596.8M; expects to fund operations beyond expected launch.
- FDA accepted atacicept BLA for priority review with PDUFA date of July 7, 2026 for IgAN.
- Matt Skelton promoted to CCO; Jane Wright-Mitchell appointed Chief Legal Officer; Christopher Hite added to board.
- Initial Phase 2 PIONEER basket trial results expected Q2 2026; pivotal eGFR data from ORIGIN 3 expected Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/0001193125-26-210351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer